These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 22923745

  • 1. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
    Kim YB, Jeung HC, Jeong I, Lee K, Rha SY, Chung HC, Kim GE.
    J Radiat Res; 2013 Jan; 54(1):52-60. PubMed ID: 22923745
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer.
    Jeong YK, Kim MS, Lee JY, Kim EH, Kim W, Ha H, Jeong JH.
    Tumori; 2013 Jan; 99(2):176-82. PubMed ID: 23748811
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
    Li Q, Hu Y, Xi M, He L, Zhao L, Liu M.
    BMC Cancer; 2012 Oct 22; 12():485. PubMed ID: 23088517
    [Abstract] [Full Text] [Related]

  • 4. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
    Jeong KY, Lee EJ, Yang SH, Seong J.
    J Radiat Res; 2015 Jan 22; 56(1):37-45. PubMed ID: 25225286
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib and radiation: a promising combination in colorectal cancer.
    Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, Robertson JM, Wilson GD.
    Int J Radiat Oncol Biol Phys; 2010 Sep 01; 78(1):213-20. PubMed ID: 20708486
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
    Kuo YC, Lin WC, Chiang IT, Chang YF, Chen CW, Su SH, Chen CL, Hwang JJ.
    Biomed Pharmacother; 2012 Feb 01; 66(1):12-20. PubMed ID: 22265104
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
    Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau CW, Cheng AL, Chen KF.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):456-62. PubMed ID: 23474115
    [Abstract] [Full Text] [Related]

  • 8. The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells.
    Kim EH, Kim MS, Jung WG.
    Oncol Rep; 2014 Dec 01; 32(6):2421-8. PubMed ID: 25242034
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 01; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 10. Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
    Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E.
    J Vasc Interv Radiol; 2015 Dec 01; 26(12):1874-78.e2. PubMed ID: 26596183
    [Abstract] [Full Text] [Related]

  • 11. The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression.
    Lee JH, Shim JW, Choi YJ, Heo K, Yang K.
    Oncol Rep; 2013 Mar 01; 29(3):917-24. PubMed ID: 23314174
    [Abstract] [Full Text] [Related]

  • 12. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, Kuo SH, Cheng AL, Teng CM.
    Cancer Lett; 2015 Feb 28; 357(2):582-90. PubMed ID: 25497009
    [Abstract] [Full Text] [Related]

  • 13. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Roh JL, Kim EH, Jang H, Shin D.
    Free Radic Biol Med; 2017 Mar 28; 104():1-9. PubMed ID: 28057599
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
    Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ.
    Clin Cancer Res; 2000 Jun 28; 6(6):2513-20. PubMed ID: 10873107
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
    Milosevic MF, Townsley CA, Chaudary N, Clarke B, Pintilie M, Fan S, Glicksman R, Haider M, Kim S, MacKay H, Yeung I, Hill RP, Fyles A, Oza AM.
    Int J Radiat Oncol Biol Phys; 2016 Jan 01; 94(1):111-117. PubMed ID: 26547383
    [Abstract] [Full Text] [Related]

  • 16. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
    Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, Cook JA.
    Clin Cancer Res; 2010 Apr 01; 16(7):2076-84. PubMed ID: 20233881
    [Abstract] [Full Text] [Related]

  • 18. Synergistic effect of sorafenib with ionizing radiation on human oral cancer cells.
    Hsu FT, Chang B, Chiang IT, Wu TH, Hwang JJ.
    In Vivo; 2014 Apr 01; 28(5):925-33. PubMed ID: 25189909
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ.
    Oncotarget; 2016 Dec 20; 7(51):85450-85463. PubMed ID: 27863427
    [Abstract] [Full Text] [Related]

  • 20. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.